Navigation Links
Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
Date:1/5/2012

EAST BRUNSWICK, N.J., Jan. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time.  The conference will be held at the Seminole Hard Rock Hotel in Hollywood, Florida.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.
Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at 

SOURCE Savient Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
2. Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
3. Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
4. Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
5. Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
6. Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
7. Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
8. Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
9. Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
10. Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
11. Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... , July 28, 2014  Some 2,500 scientists ... month in Montreal for the ... -- a discipline that draws researchers from fields as ... problems as diverse as designing new manufacturing processes to ... a special time because the United Nations has declared ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
(Date:7/28/2014)... July 28, 2014  UBM Medica US announces that ... community for medical imaging professionals, explored the complex situation ... models . The shift from fee-for-service has ... the radiologist,s reimbursement is determined in the new payment ... leaders in the field, who recognized the complexity of ...
Breaking Medicine Technology:All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 2All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 3All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 4All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 5All About Crystals: Tiny, Giant, from Mars, from Earth's Mantle, in Medicine and in Manufacturing 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2Diagnostic Imaging Delves into Measuring the Radiologist's Value 2
... 28 VIVUS, Inc. (Nasdaq: VVUS ) ... (CRL) from the U.S. Food and Drug Administration (FDA) ... new drug QNEXA® (phentermine/topiramate) Controlled-Release Capsules. The FDA issued ... cannot be approved in its present form.  The application ...
... Oct. 28 Thoratec Corporation (Nasdaq: THOR ... therapies to save, support and restore failing hearts, said ... 2010 increased 40 percent versus the third quarter of ... the third quarter and first nine months of 2010 ...
Cached Medicine Technology:FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 2FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 3FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 4FDA Issues Complete Response Letter to VIVUS Regarding New Drug Application for QNEXA® 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 2Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 3Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 4Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 5Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 6Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 7Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 8Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 9Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 10Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 11Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 12Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 13Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 14Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 15Thoratec Reports 40 Percent Increase in Third Quarter Revenues From Continuing Operations 16
(Date:7/28/2014)... 2014 Quincy Bioscience, makers of the ... to announce the release of the fourth edition of ... co-founder Mark Underwood. , The Brain Health Guide is ... techniques for readers to improve memory and promote optimal ... The Brain Health Guide provides ways to help minimize ...
(Date:7/28/2014)... Randy Dotinga HealthDay ... Scientists know it takes humans just milliseconds to look at ... Now, a new study finds that certain facial features seem ... The shape and size of the mouth, for example, ... dimensions are keys to attractiveness. The study findings ...
(Date:7/28/2014)... 2014 Ticket Down is reliable ... in Dallas, TX at the Cotton Bowl. The 2014 ... USA and it is an eight team tourney. The ... including teams from La Liga, Serie A, English Premier League, ... it out on the pitch include: Manchester United, Manchester ...
(Date:7/28/2014)... Glutamine is the most abundant single amino ... conditionally essential during times when the body undergoes large ... Immune System Support. , Having a heavy work out ... with additional glutamine may be advantageous. Glutamine supplementation may ... digestion and immune system function. Stress on the body ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, ... who are at risk of contracting meningitis because of ... according to updated recommendations from the largest pediatrician group ... for the potentially deadly infection should continue for adolescents ... In its first statement on meningococcal vaccines since ...
Breaking Medicine News(10 mins):Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3
... Italians, conducted by Henley Management College and the University of ... the age of 65 is significantly higher than it ... this study was to make the first step in the ... of prescribing funds. ,The research found that the ...
... University researcher is experimenting with ways to add fibre to ... our favourite snacks . ,Sajid Alavi is an ... of Agriculture. ,His expertise is in extrusion ... to pet food. ,Alavi is researching how ...
... found a strong relationship between negative mood and multiple ... London Health Sciences Centre , London, Canada, said that ... importance of couples emotional health during IVF treatment, and ... ,A reduction in the incidence of multiple pregnancies with ...
... delivery company, announced positive results from its Phase ... each containing a progestin and an estrogen . ... study, investigating the delivery of a formulation combining Nestorone ... of the combination formulation was applied to the forearm ...
... Now all those doting dads will be given some tips ... e-mails . ,The British government is hoping that ... to support parents will appeal to fathers, as it makes ... electronic organisers and instant messaging. ,Under the ...
... A tongue-tying device that effectively pulls the tongue closer to ... treating problems of snoring and sleep apnea, suggest early results ... of respiratory organs and the resulting sound due to obstructed ... soft or loud and unpleasant. It can sometimes be frustrating ...
Cached Medicine News:Health News:Now, Fibre-enriched Tasty Snacks in the Making 2Health News:Womens Mood Plays a Key Role in Infertility Treatment 2Health News:Contraceptive Spray Shows Positive Clinical Trial Result 2Health News:New Device to Treat Snoring and Sleep Apnea 2
Threaded cannula for use with Suretac® II, sterile packs, box of 10....
... Blitz Suture Retriever is for arthroscopic and open ... design eliminates complicated procedural steps. It may ... suture material and in conjunction with,anchors or screws ... small, curved needle tip permits the placement of ...
Suture retriever forceps...
Knot pusher/suture retriever...
Medicine Products: